X.g
Hypersensitivity reaction (may involve skin, throat and/or airways)
Hypersensitivity and infusion reactions. See also under 'Anaphylaxis' (Xf). Hypersensitivity reactions include the rapid development of malaise, cough, dyspnea, wheezing-bronchospasm, cutaneous rash, itching and pruritus. These symptoms may annunciate the onset of anaphylaxis (see Xf) especially if the drug is continued or the patient is inadvertenly rechallenged with the drug. Desensitization can be offered (PMID 26895621), so that patients can receive full treatment courses and need not be switched to an alternative, potentially more toxic or inferior therapy. See PMID 12634903, 12721396, 22149339, 22987983. Skin manifestations at PMID 24820798
Causative drugs
68
Alemtuzumab
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.ac X - Systemic reactions, syndromes and conditions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic) XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.ac X - Systemic reactions, syndromes and conditions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic) XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
1
Allergen immunotherapy
X.f
X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
2
Amphotericin B
I.d
I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging) II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.r X - Systemic reactions, syndromes and conditions
X.r - Fluid retention XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute) XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging) II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.r X - Systemic reactions, syndromes and conditions
X.r - Fluid retention XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute) XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
2
Aprotinin
II.b
II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism VI.u VI - Pulmonary vasculopathy
VI.u - Pulmonary vascular microthrombi X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
II.b - ARDS IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism VI.u VI - Pulmonary vasculopathy
VI.u - Pulmonary vascular microthrombi X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
2
Avelumab
X.g
X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
1
Azathioprine
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis) I.ah I - Interstitial/parenchymal lung disease
I.ah - Acute restrictive lung dysfunction II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.o X - Systemic reactions, syndromes and conditions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet) XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic) XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib) XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XV.bq XV - Pulmonary pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis) I.ah I - Interstitial/parenchymal lung disease
I.ah - Acute restrictive lung dysfunction II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.o X - Systemic reactions, syndromes and conditions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet) XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic) XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib) XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XV.bq XV - Pulmonary pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
1
BCG therapy (topical, via bladder instillations)
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS IV.d IV - Airway involvement
IV.d - Cough (lone) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause ARF) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.l X - Systemic reactions, syndromes and conditions
X.l - Systemic granulomatosis other than Xk X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules) XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.i XVII - Infections & related conditions
XVII.i - M. bovis (BCG) infection (topical - systemic)
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS IV.d IV - Airway involvement
IV.d - Cough (lone) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause ARF) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.l X - Systemic reactions, syndromes and conditions
X.l - Systemic granulomatosis other than Xk X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XVI.u XVI - Imaging
XVI.u - Imaging: A miliary pattern (diffuse random micronodules) XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.i XVII - Infections & related conditions
XVII.i - M. bovis (BCG) infection (topical - systemic)
2
Basiliximab
II.a
II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.u X - Systemic reactions, syndromes and conditions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection - Pneumonia
2
Brentuximab vedotin
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
1
Carboplatin
II.b
II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
II.b - ARDS IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
3
Cetuximab
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
3
Chemotherapy, antineoplastic
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS II.c II - Pulmonary edema - ARDS - Acute respiratory failure
II.c - ARDS and the hemolytic-uremic syndrome (HUS) II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Acute/subacute pulmonary edema, cardiogenic III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia) IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.c X - Systemic reactions, syndromes and conditions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr) X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction X.n X - Systemic reactions, syndromes and conditions
X.n - Tumor lysis syndrome (TLS) XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute) XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic) XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) XV.l XV - Pulmonary pathology
XV.l - Path: Pulmonary fibrosis, unclassifiable XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.am XV - Pulmonary pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo) XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic) XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS II.c II - Pulmonary edema - ARDS - Acute respiratory failure
II.c - ARDS and the hemolytic-uremic syndrome (HUS) II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Acute/subacute pulmonary edema, cardiogenic III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia) IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis X.c X - Systemic reactions, syndromes and conditions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr) X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction X.n X - Systemic reactions, syndromes and conditions
X.n - Tumor lysis syndrome (TLS) XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute) XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic) XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) XV.l XV - Pulmonary pathology
XV.l - Path: Pulmonary fibrosis, unclassifiable XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD) XV.am XV - Pulmonary pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo) XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic) XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
3
Cisplatin
I.c
I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
2
Clopidogrel
I.c
I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage III.c III - Pulmonary hemorrhage
III.c - Hemoptysis V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf VIII.k VIII - Upper, central, large airway involvement
VIII.k - Submucosal airway petechiae/hemorrhage X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.q X - Systemic reactions, syndromes and conditions
X.q - Systemic inflammatory response XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression)
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage III.c III - Pulmonary hemorrhage
III.c - Hemoptysis V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion V.n V - Pleural and/or pericardial involvement
V.n - Hemopericardium - Bloody pericardial effusion VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf VIII.k VIII - Upper, central, large airway involvement
VIII.k - Submucosal airway petechiae/hemorrhage X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.q X - Systemic reactions, syndromes and conditions
X.q - Systemic inflammatory response XI.k XI - Miscellaneous
XI.k - Esophageal hematoma (may cause chest pain and/or tracheal compression)
1
Docetaxel
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS II.j II - Pulmonary edema - ARDS - Acute respiratory failure
II.j - Transient pulmonary opacities III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage X.c X - Systemic reactions, syndromes and conditions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.r X - Systemic reactions, syndromes and conditions
X.r - Fluid retention XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pulmonary pathology
XV.h - Path: Pulmonary fibrosis (NSIP-f pattern) (see also Ig)
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS II.j II - Pulmonary edema - ARDS - Acute respiratory failure
II.j - Transient pulmonary opacities III.a III - Pulmonary hemorrhage
III.a - Alveolar hemorrhage X.c X - Systemic reactions, syndromes and conditions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.r X - Systemic reactions, syndromes and conditions
X.r - Fluid retention XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade XV.a XV - Pulmonary pathology
XV.a - Path: NSIP-c (cellular ILD) pattern (see also Ia, Ib) XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pulmonary pathology
XV.h - Path: Pulmonary fibrosis (NSIP-f pattern) (see also Ig)
2
Doxycycline
X.d
X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.o X - Systemic reactions, syndromes and conditions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic reactions, syndromes and conditions
X.f - Anaphylaxis X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways) X.o X - Systemic reactions, syndromes and conditions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
1
Efavirenz
I.c
I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) X.a X - Systemic reactions, syndromes and conditions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) X.a X - Systemic reactions, syndromes and conditions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
1